282 related articles for article (PubMed ID: 25614027)
1. Sequence and structural determinants of human APOBEC3H deaminase and anti-HIV-1 activities.
Mitra M; Singer D; Mano Y; Hritz J; Nam G; Gorelick RJ; Byeon IJ; Gronenborn AM; Iwatani Y; Levin JG
Retrovirology; 2015 Jan; 12():3. PubMed ID: 25614027
[TBL] [Abstract][Full Text] [Related]
2. APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1.
Ooms M; Krikoni A; Kress AK; Simon V; Münk C
J Virol; 2012 Jun; 86(11):6097-108. PubMed ID: 22457529
[TBL] [Abstract][Full Text] [Related]
3. Flexibility in Nucleic Acid Binding Is Central to APOBEC3H Antiviral Activity.
Bohn JA; DaSilva J; Kharytonchyk S; Mercedes M; Vosters J; Telesnitsky A; Hatziioannou T; Smith JL
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578294
[TBL] [Abstract][Full Text] [Related]
4. The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity.
Ooms M; Majdak S; Seibert CW; Harari A; Simon V
J Virol; 2010 Aug; 84(16):7961-9. PubMed ID: 20519396
[TBL] [Abstract][Full Text] [Related]
5. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.
Binka M; Ooms M; Steward M; Simon V
J Virol; 2012 Jan; 86(1):49-59. PubMed ID: 22013041
[TBL] [Abstract][Full Text] [Related]
6. Human cytidine deaminase APOBEC3H restricts HIV-1 replication.
Dang Y; Siew LM; Wang X; Han Y; Lampen R; Zheng YH
J Biol Chem; 2008 Apr; 283(17):11606-14. PubMed ID: 18299330
[TBL] [Abstract][Full Text] [Related]
7. The resistance of human APOBEC3H to HIV-1 NL4-3 molecular clone is determined by a single amino acid in Vif.
Ooms M; Letko M; Binka M; Simon V
PLoS One; 2013; 8(2):e57744. PubMed ID: 23469063
[TBL] [Abstract][Full Text] [Related]
8. The Structural Interface between HIV-1 Vif and Human APOBEC3H.
Ooms M; Letko M; Simon V
J Virol; 2017 Mar; 91(5):. PubMed ID: 28031368
[TBL] [Abstract][Full Text] [Related]
9. Mapping Region of Human Restriction Factor APOBEC3H Critical for Interaction with HIV-1 Vif.
Nakashima M; Tsuzuki S; Awazu H; Hamano A; Okada A; Ode H; Maejima M; Hachiya A; Yokomaku Y; Watanabe N; Akari H; Iwatani Y
J Mol Biol; 2017 Apr; 429(8):1262-1276. PubMed ID: 28336404
[TBL] [Abstract][Full Text] [Related]
10. Highly-potent, synthetic APOBEC3s restrict HIV-1 through deamination-independent mechanisms.
McDonnell MM; Karvonen SC; Gaba A; Flath B; Chelico L; Emerman M
PLoS Pathog; 2021 Jun; 17(6):e1009523. PubMed ID: 34170969
[TBL] [Abstract][Full Text] [Related]
11. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
12. A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity.
Zhen A; Wang T; Zhao K; Xiong Y; Yu XF
J Virol; 2010 Feb; 84(4):1902-11. PubMed ID: 19939923
[TBL] [Abstract][Full Text] [Related]
13. Reduced APOBEC3H variant anti-viral activities are associated with altered RNA binding activities.
Zhen A; Du J; Zhou X; Xiong Y; Yu XF
PLoS One; 2012; 7(7):e38771. PubMed ID: 22859935
[TBL] [Abstract][Full Text] [Related]
14. APOBEC3C Tandem Domain Proteins Create Super Restriction Factors against HIV-1.
McDonnell MM; Crawford KHD; Dingens AS; Bloom JD; Emerman M
mBio; 2020 Apr; 11(2):. PubMed ID: 32345636
[TBL] [Abstract][Full Text] [Related]
15. Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1.
Tan L; Sarkis PT; Wang T; Tian C; Yu XF
FASEB J; 2009 Jan; 23(1):279-87. PubMed ID: 18827027
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants.
Smith JL; Izumi T; Borbet TC; Hagedorn AN; Pathak VK
J Virol; 2014 Sep; 88(17):9893-908. PubMed ID: 24942576
[TBL] [Abstract][Full Text] [Related]
17. APOBEC3 degradation is the primary function of HIV-1 Vif determining virion infectivity in the myeloid cell line THP-1.
Ikeda T; Shimizu R; Nasser H; Carpenter MA; Cheng AZ; Brown WL; Sauter D; Harris RS
mBio; 2023 Aug; 14(4):e0078223. PubMed ID: 37555667
[TBL] [Abstract][Full Text] [Related]
18. Differential Activity of APOBEC3F, APOBEC3G, and APOBEC3H in the Restriction of HIV-2.
Meissner ME; Willkomm NA; Lucas J; Arndt WG; Aitken SF; Julik EJ; Baliga S; Mansky LM
J Mol Biol; 2022 Jan; 434(2):167355. PubMed ID: 34774569
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 competition experiments in humanized mice show that APOBEC3H imposes selective pressure and promotes virus adaptation.
Nakano Y; Misawa N; Juarez-Fernandez G; Moriwaki M; Nakaoka S; Funo T; Yamada E; Soper A; Yoshikawa R; Ebrahimi D; Tachiki Y; Iwami S; Harris RS; Koyanagi Y; Sato K
PLoS Pathog; 2017 May; 13(5):e1006348. PubMed ID: 28475648
[TBL] [Abstract][Full Text] [Related]
20. The Role of RNA in HIV-1 Vif-Mediated Degradation of APOBEC3H.
Wang J; Becker JT; Shi K; Lauer KV; Salamango DJ; Aihara H; Shaban NM; Harris RS
J Mol Biol; 2019 Dec; 431(24):5019-5031. PubMed ID: 31628948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
